Adding an immune therapy drug to standard chemotherapy for colorectal cancer that returns early

This trial is testing whether adding a medication called serplulimab to your standard chemotherapy and targeted therapy can help if your colorectal cancer has come back within a year after your initial treatment. Serplulimab is an immunotherapy drug that helps your body's immune system fight cancer cells. The trial will compare people who receive the medication alongside chemotherapy to those who receive chemotherapy alone.

Colorectal cancer that comes back early (within the first year) is particularly hard to treat and often doesn't respond well to standard second-line chemotherapy alone. Most of these cancers don't respond to common immune therapies by themselves, so researchers want to see if combining this medication with chemotherapy might improve outcomes for patients in this difficult situation.